We are live on ! Find out more
RVPH

REVIVA PHARMA HLDGS INC

Delisted

RVPH was delisted on the 13th of May, 2026.

12 hedge funds and large institutions have $10.5M invested in REVIVA PHARMA HLDGS INC in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1212 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

0.46% less ownership

Funds ownership: 1.44%0.97% (-0.46%)

17% less capital invested

Capital invested by funds: $12.8M → $10.5M (-$2.23M)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
12
Holders Change
Holders Change %
0%
% of All Funds
0.21%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
2
Reduced
3
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
TCM
1
Tang Capital Management
California
$4.88M
AC
2
Armistice Capital
New York
$2.57M -$331K -4,200 -12%
Vanguard Group
3
Vanguard Group
Pennsylvania
$2.07M -$80.5K -1,020 -4%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$313K +$36.5K +462 +14%
ECM
5
EMC Capital Management
Texas
$265K
BlackRock
6
BlackRock
New York
$136K +$59.8K +758 +83%
Susquehanna International Group
7
Susquehanna International Group
Pennsylvania
$108K +$105K +1,332 New
Bank of America
8
Bank of America
North Carolina
$101K +$97.9K +1,240 New
HF
9
HRT Financial
New York
$54K +$53.1K +673 New
Northern Trust
10
Northern Trust
Illinois
$43K
UBS Group
11
UBS Group
Switzerland
$6K -$1.81K -23 -23%
TRCT
12
Tower Research Capital (TRC)
New York
-$61K -624 Closed
Renaissance Technologies
13
Renaissance Technologies
New York
-$55K -563 Closed
DC
14
Davenport & Co
Virginia
-$49K -500 Closed

RVPH Hedge Fund Activity: Q3 2021 in Review

12 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q3 2021, worth a combined $10.5M — down 17% from $12.8M a quarter earlier.

Fund positioning in RVPH was balanced in Q3 2021: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 3 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $105K. The largest seller was Armistice Capital, cutting an estimated $331K.

  • 12 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q3 2021, unchanged from Q2 2021.
  • Funds reported $10.5M of REVIVA PHARMA HLDGS INC stock for Q3 2021, down 17% quarter-over-quarter.
  • 3 funds opened new REVIVA PHARMA HLDGS INC positions in Q3 2021 and 3 closed out, a net change of 0 holders.
  • The largest REVIVA PHARMA HLDGS INC buyer in Q3 2021 was Susquehanna International Group, an estimated $105K added.
  • The largest REVIVA PHARMA HLDGS INC seller in Q3 2021 was Armistice Capital, an estimated $331K sold.

Based on aggregated 13F filings for Q3 2021.